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Abstract: Pemphigus vulgaris (PV) is an autoimmune blistering disease characterized 
by the presence of IgG autoantibodies againstDsg3. Our aim was to investigate the 
molecular events implicated in the development and localization of apoptosis and 
acantholysis in PV. We used a passive transfer mouse model together with 
immunohistochemical (IHC) techniques and the TUNEL assay, with quantification 
analysis in the basal layer of the epidermis. The activated signalling molecules analysed 
and apoptotic cells detected showed an identical localization. Herein, we found for the 
first time in vivo an increased expression of activated HER receptor isoforms in the 
basal layer in PV lesions. Besides, we observed the almost total lack of activated Akt 
compared with a higher level of activated mTOR within the basal cells of the epidermis. 
Our observations strongly support that the restriction of acantholysis to the basal layer 
may be due, at least in part, to the selective and increased presence of activated HER 
receptor isoforms in these cells. After phosphorylation of HER receptor isoforms, 
intracellular signalling pathways are activated in the basal layer. In addition, the 
imbalance in Akt⁄mTOR that takes place in the basal cells may provide intracellular 
signals necessary for the development of apoptosis and acantholysis. 
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INTRODUCTION 
 
Pemphigus vulgaris (PV) is an autoimmune mucocutaneous disease characterized by 
intraepidermal blisters and autoantibodies against desmosomal cadherin desmoglein 
(Dsg) 1 and⁄or 3 (1,2). The mechanisms of blister formation in PV are still uncertain. It 
has long been known that the IgG fraction of patients’ sera is necessary and sufficient to 
produce acantholysis in in vivo experimental models (3). Müller et al. have recently 
postulated that PV-IgG against extracellular domains of Dsg3 relates to type of PV (4). 
Acantholysis is triggered in suprabasal keratinocytes through mechanisms mediated by 
the PV-IgG, including: direct inhibition of the extracellular Dsg3 adhesive ability of 
autoantibodies binding to Dsg3 and⁄or interference of desmosomal cadherin-bound 
autoantibodies with intracellular signalling pathways (5). Moreover, the multiple-hit (6) 
and basal cell shrinkage hypotheses (7) reconcile recent findings related to the 
pathogenesis of PV. 
  
Receptor tyrosine kinases (RTK) are a subgroup of transmembrane proteins with an 
intrinsic tyrosine kinase activity which determines several cellular functions as diverse 
as growth, differentiation, cell motility, cellular adhesion or survival (8). The epidermal 
growth factor receptors (EGFR) family of RTKs consists of four members: EGFR (also 
known as ErbB1 or HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). They 
are activated by the ligand- or non-ligand-dependent form (8). It is interesting to 
underline that HER receptors acquire distinct intracellular signalling properties 
depending on their dimerization partner (9). The three best characterized intracellular 
signalling pathways induced through HER receptors are mitogen activated protein-
kinases, phosphatidylinositol-3-kinase⁄protein-kinase B and phospholipase C-protein 
kinase C pathways (10). Several studies using cultures of keratinocytes have provided 
evidence for a role of the epidermal EGFR in the assembly or disassembly of the 
adherens and desmosomal junctions (11–13). EGFR may be involved in the activation 
of intracellular pathways in the acantholytic process in PV (14,15). In addition, Src 
kinase may also take part in PV acantholysis by phosphorylation of EGFR and also by 
mediating keratin aggregation of keratinocytes as well (15). 
 
Apoptosis is a process characterized by a series of dramatic perturbations to the cellular 
architecture that con-tribute not only to cell death, but also prepare cells for removal by 
phagocytes and prevent unwanted immune responses (16). In several studies, an 
activation of the apoptosis mechanism in acantholytic PV cells has been observed 
(14,17–20). Akt and mTOR kinases have been involved in the regulation of cell 
survival, and they are considered as mediators of survival or death of cells (21– 24). In 
fact it is known that mTOR integrates signals mediated by growth factors, and is 
involved in signalling downstream of Akt in PI3K pathway. It has also been described 
that mTOR may take part in the apoptotic pathway activated by damaged microtubules 
(25). The role of mTOR may be shown as part of the mTORC1 and mTORC2 
complexes (26). 
 
Currently, in vivo experiments using the EGFR inhibitor erlotinib (27), the mTOR 
inhibitor rapamycin (28), the Src inhibitor PP1 (29) and pan-caspase inhibitors (30) 
have been successfully employed to explore the involvement of these signalling 
molecules in several inflammatory diseases. 
 
Based on the above findings, our aim in this study was to explore if the increased level 
of activated HER receptor isoforms, PI3K⁄Akt pathway and mTOR kinase activity may 
take part in both apoptotic and acantholytic processes in PV lesions in a mouse model. 
Herein, we observed for the first time in vivo an increase of activated HER isoforms 
other than EGFR in the basal cells of the epidermis after injection of PV-IgG in mice. 
Furthermore, our findings revealed that the imbalance in Akt⁄mTOR activities caused by 
PV-IgG within the basal cells may provide the intracellular signals necessary for the 
development of apoptosis and acantholysis in PV. This Akt⁄mTOR imbalance may 
depend on the activation of HER receptor isoforms and the downstream intracellular 
signalling pathways subsequently triggered in basal cells. Moreover, the activation of 
HER receptors in basal cells together with the absence of Akt in these cells may explain 
the restriction of acantholysis to the basal layer of epidermis in PV. 
 
 
 
MATERIAL AND METHODS 
 
Human sera 
Our study was based on experiments utilizing IgG fractions isolated from sera of three 
PV patients with active lesions on oral mucosa and skin, and serum of a healthy donor 
[normal human serum (NHS)]. The Ethics Committee of the University Clinic of 
Navarra approved this study. All of the three patients gave their signed consent to use 
their sera for experimental studies. The three sera contain IgG against the epidermal 
intracellular substance, showing the indirect IF titre of 1.320 for PV1, 1:640 for PV2 
and 1:320 for PV3. All PV sera contained IgG autoantibodies to Dsg1 and Dsg3 as 
determined by ELISA (MBL Naka-Ku, Nagoya 460-002, Japan) and 
immunoprecipitation (31). Normal donor serum showed negative anti-epidermal 
autoantibody titre and anti-Dsg1 and anti-Dsg3 antibodies were not found. 
 
IgG fractions from the PV patients and the normal human donor were prepared as 
previously described elsewhere (31). Briefly, IgG fractions were precipitated with 50% 
ammonium sulphate, followed by affinity chromatography on Staphylococcus protein A 
conjugated to agarose beads. Bounded IgG was eluted with 0.2 M glycine⁄HCl, pH 3, 
dialysed extensively against phosphate-buffered saline (PBS), pH 7.4, concentrated by 
ultrafiltration (Amicon, Beverly, MA, USA), filter-sterilized and stored at —40°C until 
use. Protein concentration was determined by the Bradford assay (32). The IgG 
concentration in each fraction was estimated by nephelometry using goat anti-human 
IgG (Beckman Array 360 System, Holliston, MA, USA). 
 
 
Testing IgG pathogenicity using the passive transfer animal model 
C57BL⁄6J mice were obtained from The Jackson Lab (Bar Harbor, ME, USA). The 
study was performed in 24- to 48-h-old neonatal mice (weighing 1.5–2.0 g) from a 
colony maintained at the Centre of Animal Control at the University of Navarra. Each 
IgG fraction was tested for pathogenicity by passive transfer experiments as previously 
described elsewhere. (31) IgG from all of the three PV and NHS sera was injected 
intradermally into the neonatal mice (2 mg⁄g) (n = 3 for each IgG) and evaluated 12 h 
later for evidence of skin blisters. This time interval for the evaluation of mice was 
based on a time course study, which demonstrated that suprabasal acantholytic process 
was evident 11 h after the injection of PV-IgG fractions. Following examination of the 
skin for blisters, animals were killed. Clinical activity in mice was evaluated 
[Nikolsky’s sign (Ns)] according to the following scale: no spontaneous disease and 
negative Ns (0), no spontaneous disease and slight Ns (1+), slight spontaneous disease 
and slight Ns (2+) and important spontaneous disease and positive Ns (3+). Skin 
biopsies from each animal included lesional skin samples for routine histological 
examination by haematoxylin⁄eosin (H&E) and immunohistochemical (IHC) staining, 
and immunofluorescence (IF) techniques. Histological examination was evaluated 
following this scale: no acantholysis (0), acantholysis in less than one-third of the skin 
biopsy (1+), acantholysis between one- and two-thirds of the biopsy (2+) and 
acantholysis in more than two-thirds of then biopsy (3+). Direct IF was considered as 
either positive or negative. 
 
 
Inhibitor treatment schedule 
All inhibitors were administered by a single intradermal injection into the back of mice 
2 h before PV-IgG administration, as described elsewhere (31). Inhibitors were diluted 
in DMSO and injected into mice (n = 3 for each inhibitor) at the following doses based 
on in vivo studies reported elsewhere: erlotinib, 100 µ⁄g body weight (EGFR, HER2 and 
HER3 inhibitors, kindly provided by OSI Pharmaceuticals, and the purity was > 95%) 
(27); mTOR activity inhibitor rapamycin, 5 µ⁄g body weight (Calbiochem, Darmstadt, 
Germany) (28); Src activity inhibitor PP1, 1 µ⁄g body weight (Calbiochem) (29) and 
pan-caspase inhibitor (cpmVAD-CHO), 1.6 µ⁄g body weight (Calbiochem) (30). Mice 
were killed 12 h after administration of PV-IgG fractions. 
 
 
Immunohistochemical staining procedure 
Tissue samples for IHC staining were fixed in zinc solution (0.1 m Tris buffer pH 7.4, 
0.5 g calcium acetate, 5.0 g zinc acetate, 5.0 g zinc chloride, pH 6.7–7.0). A tissue 
microarray was constructed from each specimen in the cohort. Tissue cores 2 mm in 
size were obtained from paraffin-embedded tissue blocks. The original H&E stained 
slides from all blocks were first reviewed under microscope to select representative 
areas of the skin. The cores were placed on the recipient microarray block using a 
Tissue Microarrayer (Beecher Instrument, Silver Spring, MD, USA). All specimens 
were represented with fourfold redundancy. The tissue microarray was then routinely 
sectioned at 4 lm thickness. These sections were dewaxed with xylene and rehydrated 
with graded ethanol. Endogenous peroxidase activity was blocked with 3% hydrogen 
peroxidase for 10 min. Before the IHC procedure, all antibodies were required for 
antigen retrieval. All sections were placed either in a citrate buffer 10 mm (pH 6.0) and 
heated in a microwave oven (Balay W-2112, 1150-700W; Madrid, Spain) for 15 min at 
maximum power and for 15 min at medium power, or in an EDTA buffer 1 mm (pH 
8.0) and heated in a microwave oven for 5 min at maximum power and for 15 min at 
medium power. Background blocking was performed with 1:20 normal goat serum 
(DAKO, Glostrup, Denmark) prior to incubation with specific antiserum. Tissue 
sections were incubated with different polyclonal antibodies purchased from Cell 
Signaling, Barcelona, Spain, and specific for: P-EGFR (Tyr992), dilution 1:100, EDTA; 
P-HER2 (Tyr877), dilution 1:50, EDTA; P-HER3 (Tyr1289), dilution 1:100, EDTA; P-
mTOR (Ser2448), dilution 1:50, citrate; P-Src (Tyr416), dilution 1:100, EDTA and P-
Akt (Ser473), dilution 1:50, citrate. In addition, the following polyclonal antibodies 
were purchased from R&D Systems, Inc, Abingdon, UK: betacellulin (AF989), dilution 
1:50, citrate; EGF (AF2028), dilution 1:20, EDTA; amphiregulin (AF1025), dilution 
1:20, EDTA; neuroregulin 3 (AF753), dilution 1:100, EDTA. Finally, mouse anti-TGF-
a polyclonal antibody was purchased from Gene Tex, Inc, TX, USA (GTX16768), 
dilution 1:200, EDTA. Sections were incubated overnight at 4°C with the primary 
antisera. The detection system used was the Envision method (K4011; Dako, CA, USA) 
consisting of a goat anti-rabbit or antimouse IgG secondary antibody coupled to a 
peroxidase labelled dextran polymer. Sections were incubated with this reagent for 30 
min at room temperature and successively washed in PBS for 5 min. Peroxidase activity 
was revealed using Vector VIP detection kit (SK4600; Vector, Orton Southgate, 
Peterborough, UK). The reaction was stopped by washing the sections in PBS. The 
sections were lightly counterstained with haematoxylin, dehydrated and mounted with 
DPX (Sigma- Aldrich, St. Louis, MO, USA). The ratio of stained cells on the basal 
layer (area of stained basal keratinocytes⁄area of total basal keratinocytes) was 
calculated using image analysis software on images acquired with a motorized Axioplan 
2ie microscope (Zeiss, Oberkochen, Germany), operated through Meta-Morph imaging 
software (Molecular Devices, Downing-town, PA, USA) and fitted with a Zeiss Axio 
Cam ICc3 camera connected to a PC equipped with image-capturing software. Image 
analysis was performed with Matlab Software (The MathWorks Inc, Natick, MA, 
USA). The segmentation algorithm was custom-designed by Dr Ortiz-de-Solorzano's 
Morphology and Imaging Laboratory (CIMA, University of Navarra) (33). 
 
 
TUNEL assay 
To evaluate apoptosis, after injection of PV and NHS-IgG fractions, and each inhibitor 
plus PV-IgG fractions, samples of mice tissues were fixed in zinc solution as explained 
earlier. The TUNEL assay was carried out following the instructions of the 
manufacturer for ApogTag® Plus peroxidase in situ apoptosis detection kit (S7101; 
Chemicon International Inc., Temecula, CA, USA), and using Vector Vip as peroxidase 
substrate (SK4600; Vector). In addition, a time course study of apoptotic process was 
performed in mice after injection of PV-IgG fractions. Quantitation of numbers of 
TUNEL-positive cells in the basal layer of the epidermis was carried out using Meta-
Morph imaging software, as described earlier. 
 
 
Statistical analysis 
Data were analysed using the spss software for Windows (SPSS Inc, Chicago, IL, 
USA). Data showing a normal distribution after assessment by the Shapiro–Wilks test 
were analysed using a Student’s t-test and if data did not show normal distribution, a 
non-parametric Mann–Whitney U-test was performed. Data are expressed as mean ± 
SD. Significance was assumed when P < 0.05. 
  
 
  
RESULTS 
 
Testing IgG pathogenicity using the passive transfer animal model 
The administration of purified NHS-IgG to mice showed neither clinical (Fig. 1a) nor 
histological detachment (Fig. 1b), and no staining for IgG by direct IF assay was 
detected. As was described in the section Materials and methods, the time for evaluation 
of mice in this study was based on our previous analyses of time course for clinical and 
histological findings after PV-IgG administration. Suprabasal acantholysis became 
evident 11 h after PV-IgG injection. Therefore, all studies in our experiments in mice 
were carried out 12 h after PV-IgG injection. All mice studied presented important Ns 
sign after 12 h of PV-IgG injection (+++⁄+++) (Fig. 1c). All samples of skin from PV-
IgG injected studied mice revealed suprabasal acantholysis in the epidermis (+++⁄+++) 
(Fig. 1d). All samples of perilesional skin obtained for direct IF assays demonstrated 
pericellular staining for IgG in basal and suprabasal cells. 
 
 
Increased levels of activated HER receptor isoforms in basal cell layer of epidermis 
after PV-IgG administration of mice 
Although some authors have described an increase of P-EGFR (P-HER1) in 
keratinocytes after PV-IgG administration, no study has analysed both the localization 
and level of activated HER isoforms in the basal cells of the epidermis in a PV mouse 
model. Therefore, firstly we studied how and where the P-HER isoforms are expressed 
in epidermis after NHS-IgG and PV-IgG administration to mice. After NHS-IgG 
injections, a scattered and very slight staining for P-HER1, P-HER2 and P-HER3 was 
observed in the basal layer of the epidermis (Fig. 2a). However, this staining was 
particularly strong in detached and non-detached basal layer of epidermis when mice 
were injected with PVIgG (Fig. 2a). A most interesting finding in our study was the 
significant elevation (P < 0.05) of the levels of all PHER isoforms after PV-IgG 
administration to mice, when compared with that in mice injected with NHS-IgG (Fig. 
2b). 
 
To establish a possible correlation between the P-HER isoforms activity and activation 
of downstream intracellular signalling pathways in basal keratinocytes in PV, we 
studied the effect of P-HER inhibitor erlotinib (inhibitor of P-HER1, P-HER2 and P-
HER3) in both clinical manifestations and the acantholytic process in mice. We could 
find no evidence of detachment of epidermis (Ns) (Fig. 1e) or suprabasal acantholysis 
(Fig. 1f). In addition, an important and significant decrease in the levels of all P-HER 
isoforms (P < 0.05) in basal cells of epidermis was observed when mice pretreated with 
erlotinib plus PV-IgG were compared with mice treated with only PV-IgG (Fig. 2a,b). 
 
 
Betacellulin, TGF-a and EGF are increased in basal layer of epidermis in PV 
lesions 
After observing that activated HER1, HER2 and HER3 receptors exhibit an important 
and relevant expression in basal cells of epidermis in PV lesions, we decided to explore 
if some of the potential ligands of HER isoforms may switch on intracellular network 
signalling in basal keratinocytes in PV lesions. Most of the ligands studied showed a 
slight pericellular expression on the membrane of the basal cells of the epidermis after 
NHS-IgG administration to mice (Fig. 3a). After PV-IgG administration, only 
betacellulin, EGF and TGF-a showed an enhanced and significant (P < 0.05) expression 
in basal layer of epidermis when compared with mice treated with NHS-IgG (Fig. 3b). 
 
 
Activated Src kinase is increased in acantholytic and non-acantholytic basal cells 
of the epidermis in PV lesions 
In addition, we investigated the relationship between the presence of P-Src and HER 
isoforms activity. Firstly, we found that P-Src was expressed in the basal cells of the 
epidermis both after PV-IgG and NHS-IgG administration to mice (Fig. 4a). However, a 
significant increased staining for P-Src was observed in the former (P < 0.05) (Fig. 4b). 
To determine if the activity of HER may affect Src activation, we pretreated mice with 
erlotinib (P-HER1, P-HER2 and P-HER3 inhibitor) before PV-IgG injection. We 
observed that P-Src levels in epidermis of these mice were significantly lower than that 
found when only PV-IgG was administered (P < 0.05) (Fig. 4a,b). These results 
indicated that Src kinase may be activated in the basal cells of the epidermis in PV 
lesions in a mouse model, at least in part, directly through P-HER receptors. In addition, 
we found that mice pretreated with Src inhibitor PP1 showed neither clinical lesions 
(positive Ns) (Fig. 1g) nor histological acantholysis (Fig. 1h). 
 
 
An imbalance in Akt ⁄mTOR activities is present in the basal cells of the epidermis 
in PV lesions  
The next step was to elucidate if the PI3K⁄Akt signalling pathway is activated in the 
basal layer of epidermis after HER receptor activation in PV lesions. We determined the 
levels of P-Akt and P-mTOR in the basal cells of the epidermis after PV-IgG injection 
in mice, and how these signalling molecules are affected by pretreatment with several 
inhibitors. Firstly, we detected that there was hardly any P-Akt staining in the basal 
cells of the epidermis after NHS-IgG or PV-IgG administration (Fig. 5a). Expression of 
P-Akt was found only in the granular layer of the epidermis. The staining for P-mTOR 
was scattered across the basal layer of the epidermis after administration of NHSIgG, 
whereas it was strong in the same localization after PV-IgG injection (Fig. 5a). Using 
quantification analysis, we observed that the level of P-Akt was similar and very low in 
the basal layer of the epidermis after both NHS-IgG and PV-IgG administration and 
also after PV-IgG plus erlotinib or PP1 injection (Fig. 5b). However, after PV-IgG 
injection, the level of P-mTOR was significantly higher in the same localization (P < 
0.05) than that detected after NHS-IgG injection (Fig. 5b). 
 
In addition, we wondered whether mTOR is activated through the HER receptor 
isoforms downstream pathways or whether other signalling molecules such as Src may 
take part in mTOR activation, as has been described elsewhere (34). Firstly, mice were 
pretreated with the HER inhibitor erlotinib, and a significant decrease in the P-mTOR 
levels (P < 0.05), in comparison with that of mice treated only with PV-IgG, was 
observed (Fig. 5a,b). Secondly, mice were pretreated with the Src inhibitor PP1. In 
these mice we found significant decreased levels of P-mTOR (P < 0.05) as compared 
with that in mice injected only with PV-IgG (Fig. 5a,b). 
 
To determine how P-mTOR contributes to PV lesions in basal acantholytic cells of the 
epidermis, we pretreated the mice with the mTOR inhibitor rapamycin and then injected 
them with PV-IgG. None of these mice showed Ns (Fig. 1i) and suprabasal acantholysis 
(Fig. 1j). 
  
 
  
Apoptosis appears before acantholysis in PV lesions, and may be abolished by 
erlotinib, rapamycin, PP1 and pan-caspase inhibitor 
Apoptotic cells in the basal layer of the epidermis were detected 8 h after PV-IgG 
administration to mice, and 3 h before the acantholytic process began (Fig. 6a). The 
increased levels of apoptotic cells in the basal layer of the epidermis after PV-IgG 
administration were statistically significant compared with the levels obtained after 
administration of NHS-IgG (P < 0.05) (Fig. 6c). Although several studies have 
described the inhibition of the acantholytic process induced by PV-IgG by pretreatment 
with caspase inhibitor, these findings have been observed only in vitro models. 
Therefore, our next step was to determine whether the same findings were applicable in 
an in vivo model. Furthermore, we wanted to clarify the relationship between 
apoptosis⁄acantholysis in our model by means of the administration of a pan-caspase 
inhibitor to mice. We found that pretreatment of mice with this inhibitor led to a 
complete absence of PV lesions as determined by clinical (Fig. 1k) and histological 
examination (Fig. 1l). 
 
In addition, when mice were pretreated with erlotinib, rapamycin, PP1 or pan-caspase 
inhibitor, a significant (P < 0.05) decreased expression of apoptotic cells in the basal 
cells of the epidermis was observed by quantification analysis of TUNEL assays, when 
these mice were compared with those treated only with PV-IgG (Fig. 6b,c). 
 
 
 
DISCUSSION 
 
The molecular mechanism of the blistering process in PV is not fully understood. 
Several studies have demonstrated that acantholysis is associated with the presence of 
apoptotic cells (14,17–20). Nevertheless, it is not fully clear how these two processes 
are related to each other in PV lesions. 
 
Recently, it has been suggested that different characteristics of basal and suprabasal 
keratinocytes, with the expression of surface receptors on the basal cell layer (7), and 
the activation of intracellular signalling pathways, may explain the selective suprabasal 
acantholysis in PV (6). Our findings show that the restriction of acantholysis to the 
basal layer is not only due to a sharp morphological difference between basal and 
suprabasal cells. We provide evidence that apoptotic and acantholytic processes are a 
consequence of both molecular differences between basal and suprabasal cells and 
molecular changes created in the basal layer of the epidermis after PV-IgG binding to 
cells. 
 
Under normal physiological conditions, HER1 expression is found mainly in the cells of 
the basal layer of the epidermis (35,36). HER2 is normally expressed in basal cells of 
the epidermis and the outer root sheath of hair follicles (37). In addition, HER3 appears 
to be expressed in all layers of the human and mouse epidermis, although expression is 
predominantly limited to the suprabasal layer (38). HER4 is not usually expressed in the 
epidermis. In our study, after PV-IgG injection to mice, P-HER1, P-HER2 and P-HER3 
showed a significant and stronger staining in the basal layer of the epidermis than that 
observed after NHS-IgG administration. Previously, it has also been described in vitro 
that EGFR (HER1) is activated after PVIgG binding to basal cell antigens (14,15). 
Moreover, the inhibition of both apoptotic and acantholytic processes observed by 
erlotinib pretreatment of mice (inhibitor of HER1, HER2 and HER3) (39,40) underlines 
the important role of P-HER isoforms activity in PV lesions in our model. Based on 
these and our findings, we may speculate that P-HER receptors in the basal layer of the 
epidermis may trigger distinct intracellular signalling pathways leading to apoptosis and 
acantholysis. 
HER receptors may switch on intracellular network signalling through two different 
mechanisms. Growth factors may stimulate HER-expressing cells through either 
paracrine or autocrine mechanisms. Besides, HER activation may be independent of 
ligands binding to the receptor. This mechanism of HER activation entails stimulation 
of cytoplasmic tyrosine kinases, such as the Jak and Src family kinases (41). Our study 
shows that HER receptors in PV lesions may be activated through a ligand-dependent 
form. In mammals, each HER ligand contains an EGF-like domain that confers binding 
specificity (36,42). Of all the ligands tested in our study of PV in vivo, we could 
observe an important and significant enhancing only for betacellulin, while TGF-a and 
EGF did not previously describe in PV. The precise role of these three ligands in 
epidermis is still unknown in PV lesions. Recently, betacellulin has been implicated in 
the regulation of hair follicle development and hair cycle induction and enhances 
angiogenesis in wounded skin (43); TGF-a and EFG may take part in proliferating and 
regulating epidermal tissue regeneration (44,45). Usually, these three ligands show a 
higher affinity for HER1⁄2 than other HER isoforms, and probably biregulin and 
heregulin present more affinity for HER3 (42). 
  
After the binding of these ligands to their receptors, selective activation of intracellular 
signalling pathways in the basal cells of the epidermis has been observed (46). We do 
not know nevertheless if up-regulation of these ligands was caused by PV-IgG binding 
to keratinocytes before acantholysis or if it was induced by cell dissociation. And the 
origin of these ligands is not yet clear, keratinocytes or some other cells. This point 
indeed is an exciting objective for future research projects on PV. 
 
Recently, a study has established that early events in acantholysis in PV are mediated by 
Src activation through phosphorylation of EGFR, and are associated with collapse of the 
cytoskeleton (15). On the contrary, other study (47) has suggested that the loss of Dsg-
mediated adhesion and keratinocyte dissociation in PV is independent of EGFR and Src 
activities. Our study demonstrated an increased and significant presence of P-Src in 
cells of the basal layer of the epidermis after PV-IgG administration. As this increase of 
P-Src was abolished by erlotinib pretreatment (inhibitor of HER isoforms activity), Src 
activation seems to be HER-dependent. Furthermore, we were able to abolish the PV-
IgG-induced apoptotic and acantholytic processes by PP1 pretreatment to mice 
(inhibitor of Src activity). Thus, these results are in agreement with previous 
observations and show a relevant molecular role of P-Src in the activation of 
intracellular signalling cascades in PV lesions in a mouse model (15,48). 
 
A large body of evidence supporting the role of EGFR and activation of mTOR in cell 
growth and proliferation in keratinocytes has been reported (49,50). However, some 
studies have demonstrated that mTOR could also mediate the apoptotic process (25). On 
the other hand, up-regulation of P-Akt promotes survival of cells types, among them 
keratinocytes (51), by regulation of some pro-apoptotic proteins such as Bad and the 
transcription factor FKHRL-1 (21,52). Although PI3K⁄Akt pathway is considered to be 
a key activator of mTOR (10), the data presented in the current study suggest that 
mTOR kinase phoshorylation could have been produced by a mechanism independent 
of this pathway in basal cells of PV lesions. Firstly, a most interesting finding in our 
study was the observation of an almost total lack of P-Akt presence in basal cells of PV 
lesions, similar to that observed after NHS-IgG injection, or erlotinib, rapamycin and 
PP1 plus PV-IgG administration. This could be explained by the fact that usually Akt is 
expressed in suprabasal and parabasal cells (postmitotic cells) in neo-natal mice 
epidermis, but not in epidermal basal cells as has been previously reported (24). In this 
sense, activation of PI3K⁄Akt pathway has been found to be a key determinant of 
keratinocyte differentiation only in suprabasal cells of the epidermis, when postmitotic 
basal cells have initiated movement towards the spinous epidermal layer (24). All of 
these data support that the very low activity of Akt may play a role in PV lesions in the 
basal acantholytic cells of the epidermis. Therefore, after HER activation by PV-IgG 
binding to basal cells, an imbalance in Akt⁄mTOR may be generated as a consequence 
of the up-regulation of mTOR in cells with a very low activity of Akt, driving the cells 
to apoptosis. Our observation of a significant decrease in P-mTOR with no change in P-
Akt, associated with an important reduction of apoptosis and inhibition of acantholysis 
in the basal layer of the epidermis after erlotinib pretreatment, corroborates this 
suggestion. In addition, the importance of the imbalance in Akt⁄mTOR activities in PV 
lesions is highlighted with our observation of inhibition of acantholytic and apoptotic 
processes, with no change of P-Akt, in the basal layer by rapamycin pretreatment (an 
inhibitor of P-mTOR activity). Finally, another interesting finding in our study was the 
inhibition of apoptotic and acantholytic processes in the basal cells layer of the 
epidermis by pretreatment with PP1, associated with down-regulation of P-mTOR and 
with no change in P-Akt. These results suggest that in our model mTOR may be 
regulated by Src kinase, as has been described by others (34). Thus, it is tempting to 
speculate that PV-IgG causes an imbalance in Akt⁄mTOR activities within the basal 
cells of the epidermis, at least in part, as a consequence of HER receptor downstream 
signalling with activation of mTOR mediated by P-Src, without up-regulation of Akt in 
these cells. The precise roles of mTOR, as part of the mTORC1 and mTORC2 
complexes, are not yet completely understood. Taking into account that both mTORC1 
and mTORC2 may be stimulated by growth factors and that the mechanism of action of 
mTOR inhibitor rapamycin depends on the type of mTOR complex (53,54), further 
studies would be necessary to know how this kinase participates in the development of 
apoptosis and acantholysis processes in PV. 
 
Some studies suggest that Fas-L and PV-IgG induce apoptosis in PV lesions through the 
activation of caspases (17,18). Caspases may directly cleave Dsg3 and other 
desmosomal proteins, causing desmosome disruptions (55). In our study, we 
demonstrated that apoptosis may be induced by the up-regulation of P-mTOR in the 
basal cells of the epidermis, which has been shown to induce downstream 
phosphorylation of Bcl-2 (25). Our findings indicate that mTOR activation induced by 
PV-IgG may firstly precede and later induce activation of apoptosis, as rapamycin 
administration abolished apoptosis. Desmosome disruptions may appear after apoptosis 
(20), such as was also observed in our experiments in vivo, with apoptotic cells in the 
basal layer 3 h before suprabasal acantholysis began. This may mean that the induction 
of apoptosis leads to acantholysis rather than the reverse, as some authors have 
suggested (20,56). Our observation and those from other studies (19,52) of inhibition of 
both apoptotic and acantholytic processes after pretreatment with pan-caspase inhibitor 
underline the relationship between apoptosis⁄acantholysis in PV lesions. A recent study 
(57) has established that acantholysis was observed in the absence of apoptosis in skin 
lesions from PV patients, and hence apoptosis is not required for acantholysis in PV. 
The same group affirms also that PV-IgG caused dissociation of cultured human 
keratinocytes without evidence of altered nuclear morphology and DNA fragmentation. 
These findings do not coincide with those of other groups (14,17– 20), including our 
present results. We do not know how this might be explained. Perhaps, an analysis of all 
these studies might lead us to explore the apoptosis mechanism in PV when we use an 
in vivo system. Only when we employ an in vivo model all potential mechanisms and 
signalling pathways are taking part in PV lesions. Nevertheless, further studies are 
necessary to clarify this issue. 
 
In summary, although all PV patients present IgG autoantibodies against Dsg3, showing 
staining around keratinocytes in the lower two-thirds of the epidermis by direct IF, the 
restriction of apoptosis and acantholysis to the basal layer is due, at least in part, to the 
selective and increased activation of HER receptors in these cells. After phosphorylation 
of HER receptors, intracellular signalling pathways are activated in the basal layer, 
thereby amplifying several fold their ability to cause apoptosis and detachment of cells 
(58). This process is mediated, at least in part, by up-regulation of P-mTOR, without 
any changes of P-Akt, through a Src-dependent mechanism (Fig. 7). The inhibition of 
apoptosis and acantholysis observed in the basal layer of the epidermis by 
administration of inhibitors of HER isoforms, Src, mTOR and caspases in our model, 
provides compelling molecular evidence that these signalling molecules should be 
considered as potential therapeutic targets in PV therapy, as has recently been described 
(59). 
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Figure 1. Clinical and histological findings after NHS-IgG and PV-IgG plus inhibitors 
administration. (a) Neither clinical nor (b) histological findings were evident after NHS-
IgG administration. (c) After PV-IgG injection, detachment of skin and (d) suprabasal 
acantholysis could be observed. When mice were pretreated with (e, f) erlotinib, (g, h) 
PP1, (i, j) rapamycin and (k, l) pan-caspase inhibitor before PV-IgG injection, neither 
clinical nor histological manifestation was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Immunohistochemical (IHC) staining and quantification of expression of 
activated HER isoforms in basal cells of the epidermis in PV lesions. (a) When mice 
were injected with NHS-IgG, IHC analysis revealed in the basal layer of the epidermis 
the presence of a slight expression of P-HER1, P-HER2 and P-HER3 (arrows). These 
expressions were stronger after injection of PV-IgG and showed an intensive staining in 
the basal cells of detached and non-detached epidermis (arrows). When mice were 
pretreated with erlotinib, we observed a decreased expression in basal layer of P-HER1, 
P-HER2 and P-HER3 compared with that observed after PV-IgG injection (bars = 25 
lm). (b) Quantification of expression for activated HER isoforms revealed an increased 
and significant staining of P-HER1, P-HER2 and P-HER3 in the basal layer of the 
epidermis after PV-IgG injection to mice, compared with that observed after NHS-IgG 
injection. After pretreatment of mice with erlotinib, staining decreased significantly for 
all of three HER isoforms, compared with that observed only after administration of 
PV-IgG. Data are mean ± SD; *P < 0.05. NHS-IgG: non-human serum IgG; PV-IgG: 
pemphigus vulgaris IgG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Study of the expression of ligands of HER isoforms by IHC analysis and 
quantification of their staining in basal cells of the epidermis. Immunohistochemical 
analysis (a) all ligands studied showed a very slight expression on basal cells of the 
epidermis. Only betacellulin, TGF-a and EGF showed a more intensive staining 
localized in basal cells of the epidermis after PV-IgG administration (arrows). Staining 
for neuroregulin and amphiregulin was similar after both PV-IgG and NHS-IgG 
administration (bars = 50 lm). (b) Quantification of expression of these ligands after 
PV-IgG injection showed only a higher and significant staining for betacellulin, TGF-a 
and EGF than that observed after NHS-IgG administration. Data are mean ± SD; *P < 
0.05. NHS-IgG: normal human serum IgG; PV-IgG: pemphigus vulgaris IgG; AF: 
amphiregulin; BTC: betacellulin; NRG: neuroregulin; TGF-a: transforming growth 
factor-a; EGF: epidermal growth factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Analysis of phosphorylated Src in the basal cells of the epidermis by 
immunohistochemial evaluation and quantification expression. Immunohistochemical 
analysis. (a) Injection of NHS-IgG into mice revealed staining for P-Src in the basal 
layer of the epidermis and follicular epithelia. After PV-IgG injection, the expression of 
P-Src was more evident in detached and non-detached basal cells of the epidermis 
(arrows). When mice were pretreated with erlotinib, the expression of P-Src decreased 
significantly (bars = 25 lm). (b) The quantification of P-Src showed an elevated and 
significant expression after PV-IgG injection than that found after NHS-IgG 
administration. When mice were pretreated with erlotinib, we observed a lower and 
significant quantification of P-Src in basal layer of epidermis than that found after only 
PV-IgG injection. Data are mean ± SD; *P < 0.05. NHS-IgG: normal human serum IgG; 
PV-IgG: pemphigus vulgaris IgG; E: erlotinib. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Immunohistochemical analysis and quantification assay of both activated Akt 
and mTOR in basal cells of the epidermis in mice. (a) Immunohistochemical analysis 
revealed practically no P-Akt expression, and focal and patchy expression of P-mTOR 
in the basal cells of the epidermis was observed after NHS-IgG administration. P-Akt 
was very scantily expressed, and staining of P-mTOR was clearly evident in basal cells 
of detached and non-detached epidermis, after administration of PV-IgG to mice 
(arrows). When mice were pretreated with erlotinib, we observed a lower expression of 
P-mTOR and no changes in expression of P-Akt. When mice were pretreated with 
rapamycin, we did not observe any changes in the expression of P-Akt. When mice 
were pretreated with PP1, we observed a lower expression of P-mTOR and no changes 
in the expression of P-Akt compared with that observed after PV-IgG injection (bars = 
25 lm). (b) When quantification analysis was carried out, we observed a similar and 
non-significant difference in the expression of P-Akt after NHS-IgG and PV-IgG 
administrations. However, expression of P-mTOR showed a higher and significant 
expression after PV-IgG injection into mice. Pretreatment of mice with erlotinib and 
PP1 demonstrated no significant differences in the expression of P-Akt, and decreased 
and significant expression of P-mTOR. Mice pretreated with rapamycin showed no 
significant changes in the expression of P-Akt. Data are mean ± SD; *P < 0.05. NHS-
IgG: non-human serum IgG; PV-IgG: pemphigus vulgaris IgG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Relationship between apoptotic and suprabasal acantholytic processes. 
Timing course of the apoptotic process after PV-IgG injection by TUNEL assay. (a) 
Epidermis of mice injected with PV-IgG began to show the presence of apoptotic cells 
in the basal layer of the epidermis 8 h after PV-IgG injection, mainly around hair 
follicles (arrows). At 9 and 10 h after PV-IgG injection, apoptotic cells could be seen 
mainly in basal layer of epidermis (arrows). At 11 h postinjection of PV-IgG, apoptosis 
of basal and upper keratinocytes was accompanied by suprabasal acantholysis (arrows) 
(bars = 50 lm). (b) TUNEL assay in epidermis of mice after NHS-IgG and PV-IgG plus 
inhibitors. (c) Quantification of expression of apoptotic cells in the basal cell of the 
epidermis. Twelve hours after PV-IgG injection into mice, a higher and more significant 
presence of TUNEL-positive cells was observed in the basal cells of the epidermis than 
that after NHS-IgG injection. A decreased and significant expression of apoptotic cells 
in basal layer of epidermis was observed after pretreatment with erlotinib, rapamycin, 
PP1 and pan-caspases inhibitor. Data are mean ± SD;*P < 0.05. NHSIgG: non-human 
serum IgG; PV-IgG: pemphigus vulgaris IgG; E: erlotinib; RP: rapamycin; PP1: 
inhibitor of Src PP1; CI: pan-caspase inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Scheme showing how acantholysis and apoptosis may be produced. An 
imbalance in Akt ⁄ mTOR is involved in PV. Usually, Akt is not found in basal cell 
layer of epidermis, and mTOR is up-regulated after binding of PV-IgG to desmoglein 
and ⁄ or non-desmoglein antigens. It is not clear if up-regulation of EGF, betacellulin 
and TGF-a is a consequence of PV-IgG binding to keratinocytes before acantholysis or 
if it was induced by cell dissociation. 
